Sapporo, Japan

Tatsuya Fujita


Average Co-Inventor Count = 9.1

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2003-2008

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Tatsuya Fujita: Innovator in Cancer Treatment

Introduction

Tatsuya Fujita is a prominent inventor based in Sapporo, Japan. He has made significant contributions to the field of cancer treatment, holding a total of seven patents. His innovative methods focus on utilizing specific compounds to combat various types of cancer.

Latest Patents

Fujita's latest patents include a method for treating adenocarcinoma, which excludes colon cancer, lung cancer, and gastric cancer. This method involves administering a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol compound. The compound is represented by a specific formula, where R denotes an acyl residue of an unsaturated higher fatty acid, and R represents a hydrogen atom. Another patent details a method for treating cancer, which encompasses various types, including epithelioma, glioma, sarcoma, melanoma, lymphoma, and leukemia. This method also utilizes sulfoquinovosylacylglycerol compounds, highlighting Fujita's focus on innovative cancer therapies.

Career Highlights

Fujita is currently associated with Toyo Suisan Kaisha, Ltd., where he continues to develop groundbreaking treatments. His work has garnered attention in the medical community, particularly for its potential to improve patient outcomes in cancer care.

Collaborations

Fujita collaborates with notable colleagues, including Takayuki Yamazaki and Fumio Sugawara. Their combined expertise contributes to the advancement of cancer treatment methodologies.

Conclusion

Tatsuya Fujita's contributions to cancer treatment through his innovative patents demonstrate his commitment to improving healthcare. His work continues to inspire advancements in medical research and treatment options for patients suffering from cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…